Taiwan · Delayed Price · Currency is TWD EirGenix Company Description
EirGenix Inc. operates as a contract development and manufacturing company in Taiwan and internationally.
The company offers cell line development, process development, analytical and quality control, cGMP manufacturing mammalian and microbial system, and antibody-drug conjugate services.
It is also involved in the development of EG12014/EGI014, a Trastuzumab biosimilar, indicated for the treatment of cancer and currently under biologics license application status; EG1206A, a Pertuzumab biosimilar, indicated for the treatment of cancer and currently under Phase I stage; EG13074, indicated for the treatment of cancer and currently under Preclinical stage; TSY0110(EG12043), an antibody-drug conjugate, indicated for the treatment of cancer and currently under Preclinical stage; EG12021, Bevacizumab biosimilar, indicated for the treatment of cancer and currently under Preclinical stage; and EG62054, a biosimilar, currently under Preclinical stage.
In addition, the company manufactures and sells covid-19 antigen rapid test; and EG74032, a CRM197 carrier protein.
The company was incorporated in 2012 and is headquartered in New Taipei City, Taiwan.
| Country | Taiwan |
| Founded | 2012 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 1,000 |
| CEO | Lee-Cheng Liu |
Contact Details
Address: No. 101, Kangning Street New Taipei City Taiwan | |
| Phone | 886 2 7708 0123 |
| Website | eirgenix.com |
Stock Details
| Ticker Symbol | 6589 |
| Exchange | Taiwan Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | TWD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Lee-Cheng Liu | Chief Executive Officer |
| Hsiu-Chuan Yang | Chief Financial Officer |